Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

Steel firms increase prices

This comes amid a rise in transportation costs and high iron ore prices; long-steel producers keep prices unchanged

Sugar mills reiterate need for financial help

Lower realisation than cost of production hits financial performance in April-June quarter, industry seeks govt support

Goa postpones 5th ore auction, anticipating lack of response

State had kept 2.18 mn tonnes of low-grade ore in fifth round after successful sale 5 mn tonnes in earlier rounds

Iron ore seen slumping to $75 a tonne

The commodity used to make steel will average $80 a tonne in 2015, down from an earlier full-year estimate of $85

Markets hit record highs; Sensex ends above 27,000

The Sensex ended above 27,000 for the first time while the Nifty topped 8,100

Back to Top